Chime Biologics Limited

Based in Wuhan, China, and founded in 2013, Chime Biologics Limited provides biopharmaceutical development and manufacturing solutions. In 2021, the company raised funding from Fidelity International, Panacea Venture, and VMS Group. The company employs over 400 people. In December 2025, Chime Biologics Limited raised an undisclosed amount of Series A+ funding from new investor New City Science and Technology Innovation Capital.

Chime Biologics Limited offers integrated solutions for early-stage drug development to late-stage clinical research and commercial cGMP (current good manufacturing) production. The company’s integrated platform offers cell Line development, process development, process transfer, quality control and assurance (QC/QA), protein science characterization, clinical manufacturing (DS/DP), commercial manufacturing (DS/DP), material management & logistics, and regulatory support. Chime Biologics also provides biologics manufacturing capability for monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, and enzymes. The company’s revenue is generated by providing CDMO services for biologics development and manufacturing, including technology transfer, production, and quality assurance for pharmaceutical companies.